ClinicaliQ Trial Snapshot
- STOP-HAE: A Phase 3 Study of ADX-324 in HAE — Recruiting • Phase III • Cardiology / Cardiovascular • NCT06960213.
- What is being tested: ADX-324, a novel therapeutic agent, is being evaluated in a Phase 3 trial to assess its efficacy and safety in treating Type 1 and Type 2 hereditary angioedema (HAE), alongside pharmacokinetic/pharmacodynamic profiles and quality of life outcomes.
- Patient eligibility overview: The trial enrolls patients with confirmed Type 1 or Type 2 HAE, representing the two most common genetic variants of this rare condition affecting complement system regulation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Eligibility Snapshot
- Key Inclusion Criteria: * Age ≥18 years at the time of signing informed consent. * Have a documented diagnosis of HAE-1/HAE-2 (Type I or II) * Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening * Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist) Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.